Click image to enlarge
The
V-PLEX Platform offers analytically validated singleplex and multiplex assay kits. Developed under rigorous design control, V-PLEX kits provide accurate and reproducible results with consistency from lot to lot. The V-PLEX Custom NHP Biomarkers 1 Kit enables customization of NHP V-PLEX Panels by choosing a subset of the analytes listed below.
-
-
Specifications
-
-
Documentation
-
References
|
Analyte(s)
|
|
C-Peptide, Eotaxin, Eotaxin-3, GIP (active), GLP-1 (active), Glucagon, GM-CSF, IFN-γ, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23p40, IL-15, IL-16, IL-17A, Insulin, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, PP, TARC, TNF-β, VEGF-A
|
|
|
Species
|
|
Non-human primate
|
|
|
Instrument(s)
|
|
MESO SECTOR S 600MM
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
MESO QuickPlex SQ 120
,
SECTOR Imager 6000
,
SECTOR Imager 2400
|
|
|
Plate Type
|
|
96-well
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
SDS
|
|
-
Diluent 10, Diluent 11, Diluent 12, Diluent 13, Diluent 15, Diluent 16 and Diluent 17
-
Diluent 2, Diluent 3, Diluent 5, Diluent 7 and Diluent 8
-
Diluent 41, Diluent 43 and Diluent 45
-
Diluent 50, Diluent 56, Diluent 61, Diluent 100, and Diluent 101
-
Diluent 57, Diluent 58, and Diluent 59
-
MSD Calibrators and Controls
-
MSD GOLD Read Buffer B
-
Read Buffer T (4x), Read Buffer S (4x) and Read Buffer S (1x)
-
Wash Buffer (20X)
|
|
Title
|
Journal
|
Year
|
|
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
|
|
|
|
Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops
|
|
|
|
Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke
|
|
|
|
Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms
|
|
|
|
Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations
|
|
|
|
|
View All
|
Order Details
back
K156ARH
K156ARH-1
1 each
Call for Price
K156ARH-2
5 each
Call for Price
K156ARH-4
25 each
Call for Price
Meso Scale Japan 株式会社